SCHEMBL2126134

SCHEMBL2126134

C=CC(=O)c1ccc(F)c(F)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.59
CES1 P23141 2/20 0.59
KMT2A Q03164 3/20 0.53
MEN1 O00255 2/20 0.53
MAPT P10636 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
KDM4E B2RXH2 1/20 0.53
ALDH1A1 P00352 1/20 0.53
EGFR P00533 1/20 0.53
TP53 P04637 1/20 0.53
CYP3A4 P08684 1/20 0.53
PKM P14618 1/20 0.53
HPGD P15428 1/20 0.53
ALOX15 P16050 1/20 0.53
ALOX12 P18054 1/20 0.53
JAK1 P23458 1/20 0.53
MAPK1 P28482 1/20 0.53
HSD17B10 Q99714 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
ALDH5A1 P51649 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8871990 0.84 ALDH5A1 (0.53) CES2CES1KMT2AMEN1MAPT
SCHEMBL6990311 0.83 CES2 (0.64) CES2CES1KMT2AMEN1MAPT
SCHEMBL6990314 0.83 CES2 (0.64) CES2CES1KMT2AMEN1MAPT
SCHEMBL13977393 0.82 HDAC1 (0.56) CES2CES1KMT2AMEN1MAPT
SCHEMBL8836296 0.82 KDM4E (0.49) CES2CES1KMT2AMEN1MAPT
SCHEMBL14192544 0.82 KDM4E (0.57) CES2CES1KMT2AMEN1MAPT
SCHEMBL8780278 0.81 CES2 (0.61) CES2CES1KMT2AMEN1MAPT
Water SCHEMBL3522042 0.79 CES2 (0.59) CES2CES1KMT2AMEN1MAPT
SCHEMBL5262647 0.78 CES2 (0.56) CES2CES1KMT2AMEN1MAPT
SCHEMBL20007006 0.78 HTT (0.65) KMT2AMEN1MAPTSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105576138-B Platinum (II) isoquinoline-pyridine-benzene-based complex, preparation method thereof and organic light emitting diode prepared therefrom 港大科桥有限公司 2020-12-25 CN disclosed
CN-104926788-A Substituted piperidin derivative, and pharmaceutical composition containing substituted piperidin derivative and application thereof in antitumor UNIV ZHEJIANG 2015-09-23 CN disclosed
EP-2443132-A1 PLATINUM (II) ISOQUINOLINE-PYRIDINE-BENZENE BASED COMPLEXES, PREPARING METHOD THEREOF, AND ORGANIC LIGHT-EMITTING DIODES MADE THEREFROM Versitech Limited (CN) 2012-04-25 EP disclosed
WO-2011109470-A1 HETEROARYL NITRILE COMPOUNDS USEFUL AS INHIBITORS OF CATHEPSIN-S BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-09-09 WO disclosed
WO-2010145190-A1 PLATINUM (II) ISOQUINOLINE-PYRIDINE-BENZENE BASED COMPLEXES, PREPARING METHOD THEREOF, AND ORGANIC LIGHT-EMITTING DIODES MADE THEREFROM THE UNIVERSITY OF HONG KONG (CN) 2010-12-23 WO disclosed
CN-101730703-A Benzamide derivatives with antiproliferative activity and pharmaceutical preparations thereof RADIATION MEDICINE OF PLA MILI 2010-06-09 CN disclosed
US-20070161646-A1 Piperidine Derivatives and Their Use as Modulators of Chemokine Receptor Activity (Especially CCR5) ASTRAZENECA AB (SE) 2007-07-12 US disclosed
US-7192973-B2 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially CCR5) ASTRAZENECA AB (SE) 2007-03-20 US disclosed
US-20040267016-A1 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5) ASTRAZENECA AB (SE) 2004-12-30 US disclosed
EP-1448548-A1 PIPERIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY (ESPECIALLY CCR5) AstraZeneca AB (SE) 2004-08-25 EP disclosed
WO-2003042205-A1 PIPERIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY (ESPECIALLY CCR5) ASTRAZENECA AB (SE) 2003-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040267016-A1 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5) CCR5, CCR2, CCR1 CES2 665/4885CES1 954/4885KMT2A 4487/4885
US-20070161646-A1 Piperidine Derivatives and Their Use as Modulators of Chemokine Receptor Activity (Especially CCR5) CCR5, CCR2, CCL5 CES2 647/4885CES1 1248/4885KMT2A 4465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.